HQH - abrdn Healthcare Investors

What this means for you

Saba owned more than 5% of this fund and has since sold down below that level, so it no longer has to report its holding.

Nothing is required of you. If a large investor buys in again, the notice appears here the day it is filed.

Email me if this changes

What happened, and when

1. Nov 18, 2024

   Saba sold down below 5% and stopped reporting.

   Original document →

2. Oct 22, 2024

   Saba cut its stake to 5.3% (from 6.3%). It has said it may push for changes.

   Original document →

3. May 3, 2024

   Saba raised its stake to 6.3% (from 5.2%). It has said it may push for changes.

   Original document →

4. March 15, 2024

   Saba now owns 5.2%. It has said it may push for changes.

   Original document →

About this fund

• Run by abrdn Inc. As of Sept 30, 2025, from the fund's yearly report. Original document →
• Size: about $1.36 billion of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Borrowing: the fund does not borrow. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Costs: 1% a year in management fees; 1.1% a year in total, including interest on borrowed money. Fiscal year ended Sept 30, 2025. As of Sept 30, 2025, from the fund's yearly report. Original document →
• Payouts: last fiscal year (ended Sept 30, 2025) the fund paid $2.24 a share. $2.11 of that was income; $0.04 came from gains; $0.09 was your own money back, not income. As of Sept 30, 2025, from the fund's annual report. Original document →
• Value of holdings per share at the last fiscal year end (Sept 30, 2025): $19.70. The shares traded at $18.46, about 6.3% below that. As of Sept 30, 2025, from the fund's yearly report. Original document →
• How the holdings did: up 27.3% over the last three months we have (April-June 2026), before the share price is taken into account. Over the last 12 months: +60.7%. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• How the holdings did over the fiscal year (ended Sept 30, 2025): the value of the holdings returned +10.9%. How the share price did: the shares returned +13.5% over the same year, counting payouts and the change in the market price. As of Sept 30, 2025, from the fund's annual report. Original document →
• First reported to the regulator in 1995.

What the fund holds

Mostly shares (88%), the rest preferred shares, derivatives and cash and short-term holdings. About 84% issued in the U.S.

The fund also sells options on its holdings to raise income.

1. uniQure NV - 4.2%
2. VeraDermics - 3.4%
3. Insmed - 2.8%
4. Derivatives - 2.6%
5. Argenx SE - 2.5%
6. Veradermics, Inc. - 2.3%
7. Personalis - 2.2%
8. Tectonic Therapeutic - 1.9%
9. Oruka Therapeutics - 1.9%
10. Abbott Laboratories - 1.8%

As of June 30, 2026, from the fund's quarterly holdings report. Original document →